### Edgar Filing: TRANSDEL PHARMACEUTICALS INC - Form 3

#### TRANSDEL PHARMACEUTICALS INC

Form 3

March 02, 2010

## FORM 3

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

**SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

Person \*

NIDA TERRY

C/O TRANSDEL

PHARMACEUTICALS, INC., 4225 EXECUTIVE

**SQUARE, SUITE 485** 

(Last)

(First)

(Middle)

Statement

(Month/Day/Year)

02/26/2010

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

TRANSDEL PHARMACEUTICALS INC [TDLP]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Check all applicable)

Chief Business Officer

Director \_X\_\_ Officer (give title below) (specify below)

10% Owner Other

6. Individual or Joint/Group Filing(Check Applicable Line)

\_X\_ Form filed by One Reporting

Person Form filed by More than One

Reporting Person

LA JOLLA, Â CAÂ 92037

(City) (State)

(Street)

1. Title of Security (Instr. 4)

(Zip)

2. Amount of Securities Beneficially Owned

(Instr. 4)

Ownership

Table I - Non-Derivative Securities Beneficially Owned

4. Nature of Indirect Beneficial

Ownership (Instr. 5)

Form: Direct (D) or Indirect (I) (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying **Derivative Security** (Instr. 4)

4. 5. Ownership Conversion or Exercise Form of Price of

Derivative

6. Nature of Indirect Beneficial Ownership (Instr. 5)

Derivative Security:

### Edgar Filing: TRANSDEL PHARMACEUTICALS INC - Form 3

Date Expiration Title Amount or Security Direct (D)

Exercisable Date Number of Shares (I)

(Instr. 5)

## **Reporting Owners**

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
NIDA TERRY C/O TRANSDEL PHARMACEUTICALS, INC. 4225 EXECUTIVE SQUARE, SUITE 485 LA JOLLA, CA 92037	Â	Â	Chief Business Officer	Â

# **Signatures**

/s/ Terry Nida 03/02/2010

\*\*Signature of Date
Reporting Person

# **Explanation of Responses:**

No securities are beneficially owned

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2